Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B F El-Rayes

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
British Journal of Cancer|July 9, 2004
Targeting the epidermal growth factor receptorB F El-Rayes, P M LoRusso
Expert Opinion on Pharmacotherapy|February 5, 2002
Pancreatic cancer: the evolving role of systemic therapyN V Adsay, B F El-Rayes, P A Philip
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery|February 26, 2003
Comparison of DNA content parameters in paired, fresh tissue pretreatment biopsies and surgical resections from squamous cell carcinoma of the head and neckB F El-Rayes, Z Maciorowski, H Pietraszkiewicz, et al.
Cancer Investigation|March 20, 2003
Developments in the systemic therapy of pancreatic cancerB F el-Rayes, A F Shields, V Vaitkevicius, et al.
Current Oncology (Toronto, Ont.)|December 31, 2015
Analysis of liver-directed therapies in U.S. cancer patientsO B Alese, S Kim, Z Chen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 21, 2004
A phase II study of carboplatin and paclitaxel in esophageal cancerB F El-Rayes, A Shields, M Zalupski, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 11, 2012
mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE)H J Prajapati, J R Spivey, S I Hanish, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2003
Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancerB F El-Rayes, M M Zalupski, A F Shields, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 25, 2010
A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancersB F El-Rayes, M Zalupski, T Bekai-Saab, et al.
British Journal of Cancer|October 4, 2017
A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumoursK P Papadopoulos, B F El-Rayes, A W Tolcher, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
British Journal of Cancer|July 9, 2004
Targeting the epidermal growth factor receptorB F El-Rayes, P M LoRusso
Expert Opinion on Pharmacotherapy|February 5, 2002
Pancreatic cancer: the evolving role of systemic therapyN V Adsay, B F El-Rayes, P A Philip
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery|February 26, 2003
Comparison of DNA content parameters in paired, fresh tissue pretreatment biopsies and surgical resections from squamous cell carcinoma of the head and neckB F El-Rayes, Z Maciorowski, H Pietraszkiewicz, et al.
Cancer Investigation|March 20, 2003
Developments in the systemic therapy of pancreatic cancerB F el-Rayes, A F Shields, V Vaitkevicius, et al.
Current Oncology (Toronto, Ont.)|December 31, 2015
Analysis of liver-directed therapies in U.S. cancer patientsO B Alese, S Kim, Z Chen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 21, 2004
A phase II study of carboplatin and paclitaxel in esophageal cancerB F El-Rayes, A Shields, M Zalupski, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 11, 2012
mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE)H J Prajapati, J R Spivey, S I Hanish, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2003
Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancerB F El-Rayes, M M Zalupski, A F Shields, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 25, 2010
A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancersB F El-Rayes, M Zalupski, T Bekai-Saab, et al.
British Journal of Cancer|October 4, 2017
A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumoursK P Papadopoulos, B F El-Rayes, A W Tolcher, et al.
Pageof 2